{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:07:20Z","timestamp":1792267640178,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12035-025-05037-7","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:49:52Z","timestamp":1746683392000},"page":"11920-11934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel Dual GLP-1\/CCK Receptor Agonist Improves Cognitive Performance and Synaptogenesis in the 5\u2009\u00d7 FAD Alzheimer Mouse Model"],"prefix":"10.1007","volume":"62","author":[{"given":"He","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongrui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"1","key":"5037_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","volume":"19","author":"M Tzioras","year":"2023","unstructured":"Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL (2023) Synaptic degeneration in Alzheimer disease. Nat Rev Neurol 19(1):19\u201338. https:\/\/doi.org\/10.1038\/s41582-022-00749-z","journal-title":"Nat Rev Neurol"},{"key":"5037_CR2","doi-asserted-by":"publisher","unstructured":"Espay AJ, Kepp KP, Herrup K (2024) Lecanemab and donanemab as therapies for alzheimer's disease: an illustrated perspective on the data. eNeuro 11. https:\/\/doi.org\/10.1523\/ENEURO.0319-23.2024","DOI":"10.1523\/ENEURO.0319-23.2024"},{"issue":"15","key":"5037_CR3","doi-asserted-by":"publisher","first-page":"12486","DOI":"10.3390\/ijms241512486","volume":"24","author":"G Plascencia-Villa","year":"2023","unstructured":"Plascencia-Villa G, Perry G (2023) Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. Int J Mol Sci 24(15):12486. https:\/\/doi.org\/10.3390\/ijms241512486","journal-title":"Int J Mol Sci"},{"issue":"1\u20133","key":"5037_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2004.02.049","volume":"490","author":"S Hoyer","year":"2004","unstructured":"Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490(1\u20133):115\u2013125. https:\/\/doi.org\/10.1016\/j.ejphar.2004.02.049","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"5037_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.cmet.2012.08.012","volume":"16","author":"Mattson","year":"2012","unstructured":"Mattson, (2012) MP Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab 16(6):706\u2013722. https:\/\/doi.org\/10.1016\/j.cmet.2012.08.012","journal-title":"Cell Metab"},{"key":"5037_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fnagi.2019.00088","volume":"11","author":"C H\u00f6lscher","year":"2019","unstructured":"H\u00f6lscher C (2019) Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer\u2019s Disease. Front Aging Neurosci 11:88. https:\/\/doi.org\/10.3389\/fnagi.2019.00088","journal-title":"Front Aging Neurosci"},{"issue":"22","key":"5037_CR7","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1093\/hmg\/ddw312","volume":"25","author":"R Kandimalla","year":"2016","unstructured":"Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH (2016) Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer\u2019s disease. Hum Hum Mol Genet 25(22):4881\u20134897. https:\/\/doi.org\/10.1093\/hmg\/ddw312","journal-title":"Hum Hum Mol Genet"},{"key":"5037_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bbadis.2015.12.018","volume":"4","author":"R Kandimalla","year":"1862","unstructured":"Kandimalla R (1862) Reddy PH (2016) Multiple faces of dynamin-related protein 1 and its role in Alzheimer\u2019s disease pathogenesis. Biochim Biophys Acta 4:814\u2013828. https:\/\/doi.org\/10.1016\/j.bbadis.2015.12.018","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"5037_CR9","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/jnr.24781","volume":"99","author":"VK Medala","year":"2021","unstructured":"Medala VK, Gollapelli B, Dewanjee S, Ogunmokun G, Kandimalla R, Vallamkondu J (2021) Mitochondrial dysfunction, mitophagy, and role of dynamin-related protein 1 in Alzheimer\u2019s disease. J Neurosci Res 99(4):1120\u20131135. https:\/\/doi.org\/10.1002\/jnr.24781","journal-title":"J Neurosci Res"},{"issue":"23","key":"5037_CR10","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1093\/hmg\/ddr381","volume":"20","author":"MJ Calkins","year":"2011","unstructured":"Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer\u2019s disease. Hum Mol Genet 20(23):4515\u20134529. https:\/\/doi.org\/10.1093\/hmg\/ddr381","journal-title":"Hum Mol Genet"},{"issue":"1","key":"5037_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/dneu.20815","volume":"71","author":"SY Lee","year":"2011","unstructured":"Lee SY, Soltesz I (2011) Cholecystokinin: a multi-functional molecular switch of neuronal circuits. Dev Neurobiol 71(1):83\u201391. https:\/\/doi.org\/10.1002\/dneu.20815","journal-title":"Dev Neurobiol"},{"key":"5037_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fendo.2017.00047","volume":"8","author":"JF Rehfeld","year":"2017","unstructured":"Rehfeld JF (2017) Cholecystokinin-From Local Gut Hormone to Ubiquitous Messenger. Front Endocrinol 8:47. https:\/\/doi.org\/10.3389\/fendo.2017.00047","journal-title":"Front Endocrinol"},{"issue":"1","key":"5037_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1432-1033.1968.tb00433.x","volume":"6","author":"V Mutt","year":"1968","unstructured":"Mutt V, Jorpes JE (1968) Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem 6(1):156\u201362. https:\/\/doi.org\/10.1111\/j.1432-1033.1968.tb00433.x","journal-title":"Eur J Biochem"},{"key":"5037_CR14","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.yfrne.2024.101122","volume":"73","author":"N Reich","year":"2024","unstructured":"Reich N, H\u00f6lscher C (2024) Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer\u2019s and Parkinson\u2019s disease. Front Neuroendocrinol 73:101122. https:\/\/doi.org\/10.1016\/j.yfrne.2024.101122","journal-title":"Front Neuroendocrinol"},{"issue":"3","key":"5037_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/s0091-3057(99)00122-7","volume":"64","author":"SD Croll","year":"1999","unstructured":"Croll SD, Chesnutt CR, Greene NA, Lindsay RM, Wiegand SJ (1999) Peptide immunoreactivity in aged rat cortex and hippocampus as a function of memory and BDNF infusion. Pharmacol Biochem Behav 64(3):625\u2013635. https:\/\/doi.org\/10.1016\/s0091-3057(99)00122-7","journal-title":"Pharmacol Biochem Behav"},{"key":"5037_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neurobiolaging.2019.01.002","volume":"76","author":"A Plagman","year":"2019","unstructured":"Plagman A, Hoscheidt S, McLimans KE, Klinedinst B, Pappas C et al (2019) Cholecystokinin and Alzheimer\u2019s disease: a biomarker of metabolic function, neural integrity, and cognitive performance. Neurobiol Aging 76:201\u2013207. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2019.01.002","journal-title":"Neurobiol Aging"},{"issue":"5672","key":"5037_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/274711a0","volume":"274","author":"GJ Dockray","year":"1978","unstructured":"Dockray GJ, Gregory RA, Hutchison JB, Harris JI, Runswick MJ (1978) Isolation, structure and biological activity of two cholecystokinin octapeptides from sheep brain. Nature 274(5672):711\u2013713. https:\/\/doi.org\/10.1038\/274711a0","journal-title":"Nature"},{"issue":"9","key":"5037_CR18","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1523\/JNEUROSCI.07-09-02967.1987","volume":"7","author":"DR Hill","year":"1987","unstructured":"Hill DR, Campbell NJ, Shaw TM, Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7(9):2967\u20132976. https:\/\/doi.org\/10.1523\/JNEUROSCI.07-09-02967.1987","journal-title":"J Neurosci"},{"issue":"11","key":"5037_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0006-3223(93)90067-n","volume":"34","author":"T Suzuki","year":"1993","unstructured":"Suzuki T, Moroji T, Hori T, Baba A, Kawai N, Koizumi J (1993) Autoradiographic localization of CCK-8 binding sites in the rat brain: effects of chronic methamphetamine administration on these sites. Biol Psychiatry 34(11):781\u2013790. https:\/\/doi.org\/10.1016\/0006-3223(93)90067-n","journal-title":"Biol Psychiatry"},{"issue":"16","key":"5037_CR20","doi-asserted-by":"publisher","first-page":"7230","DOI":"10.1523\/JNEUROSCI.19-16-07230.1999","volume":"19","author":"A Sebret","year":"1999","unstructured":"Sebret A, L\u00e9na I, Cr\u00e9t\u00e9 D, Matsui T, Roques BP, Daug\u00e9 V (1999) Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci 19(16):7230\u20137237. https:\/\/doi.org\/10.1523\/JNEUROSCI.19-16-07230.1999","journal-title":"J Neurosci"},{"issue":"6","key":"5037_CR21","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/0016-5085(93)91070-x","volume":"105","author":"P Hoffmann","year":"1993","unstructured":"Hoffmann P, Eberlein GA, Reeve JR Jr, B\u00fcnte RH, Grandt D, Goebell H et al (1993) Comparison of Clearance and Metabolism of Infused Cholecystokinins 8 and 58 in Dogs. Gastroenterology 105(6):1732\u20131736. https:\/\/doi.org\/10.1016\/0016-5085(93)91070-x","journal-title":"Gastroenterology"},{"issue":"6","key":"5037_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00125-013-2878-0","volume":"56","author":"N Irwin","year":"2013","unstructured":"Irwin N, Montgomery IA, Flatt PR (2013) Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice. Diabetologia 56(6):1425\u20131435. https:\/\/doi.org\/10.1007\/s00125-013-2878-0","journal-title":"Diabetologia"},{"issue":"8","key":"5037_CR23","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.2337\/db15-0220","volume":"64","author":"N Irwin","year":"2016","unstructured":"Irwin N, Pathak V, Flatt PR (2016) A Novel CCK-8\/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice [published correction appears in diabetes. Diabetes 64(8):2996\u20133009. https:\/\/doi.org\/10.2337\/db15-0220","journal-title":"Diabetes"},{"key":"5037_CR24","doi-asserted-by":"publisher","first-page":"175029","DOI":"10.1016\/j.ejphar.2022.175029","volume":"926","author":"Y Su","year":"2022","unstructured":"Su Y, Liu N, Zhang Z, Li H, Ma J, Yuan Y et al (2022) Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and \u03b1-synuclein accumulation in the colon of two Parkinson\u2019s disease mouse models. Eur J Pharmacol 926:175029. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175029","journal-title":"Eur J Pharmacol"},{"key":"5037_CR25","doi-asserted-by":"publisher","first-page":"814430","DOI":"10.3389\/fnins.2022.814430","volume":"16","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li H, Su Y, Ma J, Yuan Y, Yu Z et al (2022) Neuroprotective effects of a cholecystokinin analogue in the 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine parkinson\u2019s disease mouse model. Front Neurosci 16:814430. https:\/\/doi.org\/10.3389\/fnins.2022.814430","journal-title":"Front Neurosci"},{"issue":"9","key":"5037_CR26","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1007\/s12035-023-03388-7","volume":"60","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Yu Z, Yuan Y, Yang J, Wang S, Ma H et al (2023) Cholecystokinin signaling can rescue cognition and synaptic plasticity in the APP\/PS1 mouse model of alzheimer\u2019s disease. Mol Neurobiol 60(9):5067\u20135089. https:\/\/doi.org\/10.1007\/s12035-023-03388-7","journal-title":"Mol Neurobiol"},{"issue":"1","key":"5037_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrneurol.2010.130","volume":"19","author":"RA Haeusler","year":"2018","unstructured":"Haeusler RA, McGraw TE, Accili D (2018) Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 19(1):31\u201344. https:\/\/doi.org\/10.1038\/nrneurol.2010.130","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"5037_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s13311-019-00755-y","volume":"16","author":"JC Ryu","year":"2019","unstructured":"Ryu JC, Zimmer ER, Rosa-Neto P, Yoon SO (2019) Consequences of metabolic disruption in Alzheimer\u2019s disease pathology. Neurotherapeutics 16(3):600\u2013610. https:\/\/doi.org\/10.1007\/s13311-019-00755-y","journal-title":"Neurotherapeutics"},{"issue":"2","key":"5037_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"AM Moloney","year":"2010","unstructured":"Moloney AM, Griffin RJ, Timmons S, O\u2019Connor R, Ravid R, O\u2019Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer\u2019s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31(2):224\u2013243. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.04.002","journal-title":"Neurobiol Aging"},{"issue":"4","key":"5037_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A et al (2012) Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316\u20131338. https:\/\/doi.org\/10.1172\/JCI59903","journal-title":"J Clin Invest"},{"issue":"1","key":"5037_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","volume":"15","author":"CM Long-Smith","year":"2013","unstructured":"Long-Smith CM, Manning S, McClean PL, Coakley MF, O\u2019Halloran DJ, Holscher C et al (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer\u2019s disease. Neuromolecular Med 15(1):102\u2013114. https:\/\/doi.org\/10.1007\/s12017-012-8199-5","journal-title":"Neuromolecular Med"},{"issue":"17","key":"5037_CR32","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci 31(17):6587\u20136594. https:\/\/doi.org\/10.1523\/JNEUROSCI.0529-11.2011","journal-title":"J Neurosci"},{"issue":"Pt 4","key":"5037_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","volume":"76","author":"PL McClean","year":"2014","unstructured":"McClean PL, H\u00f6lscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease. Neuropharmacology 76(Pt 4):57\u201367. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.005","journal-title":"Neuropharmacology"},{"key":"5037_CR34","doi-asserted-by":"publisher","first-page":"109952","DOI":"10.1016\/j.neuropharm.2024.109952","volume":"253","author":"C H\u00f6lscher","year":"2024","unstructured":"H\u00f6lscher C (2024) Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: A revolution in the making? Neuropharmacology 253:109952. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109952","journal-title":"Neuropharmacology"},{"issue":"S9","key":"5037_CR35","doi-asserted-by":"publisher","first-page":"e057848","DOI":"10.1002\/alz.057848","volume":"17","author":"P Edison","year":"2021","unstructured":"Edison P, Femminella GD, Ritchie CW, Holmes C, Walker Z, Ridha BH et al (2021) Evaluation of Liraglutide in the Treatment of Alzheimer\u2019s Disease. Alzheimers Dement 17(S9):e057848. https:\/\/doi.org\/10.1002\/alz.057848","journal-title":"Alzheimers Dement"},{"issue":"S21","key":"5037_CR36","doi-asserted-by":"publisher","first-page":"e080538","DOI":"10.1002\/alz.080538","volume":"19","author":"P Edison","year":"2023","unstructured":"Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z et al (2023) MRI changes following treatment of GLP-1 analogue, liraglutide in Alzheimer\u2019s disease. Alzheimers Dement 19(S21):e080538. https:\/\/doi.org\/10.1002\/alz.080538","journal-title":"Alzheimers Dement"},{"issue":"9","key":"5037_CR37","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","volume":"9","author":"MJ During","year":"2003","unstructured":"During MJ, Cao L, Zuzga DS et al (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9(9):1173\u20131179. https:\/\/doi.org\/10.1038\/nm919","journal-title":"Nat Med"},{"issue":"1","key":"5037_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbr.2009.06.035","volume":"205","author":"T Abbas","year":"2009","unstructured":"Abbas T, Faivre E, H\u00f6lscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer\u2019s disease. Behav Brain Res 205(1):265\u2013271. https:\/\/doi.org\/10.1016\/j.bbr.2009.06.035","journal-title":"Behav Brain Res"},{"issue":"10","key":"5037_CR39","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S (2015) Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4(10):718\u2013731. https:\/\/doi.org\/10.1016\/j.molmet.2015.07.008","journal-title":"Mol Metab"},{"key":"5037_CR40","doi-asserted-by":"publisher","first-page":"109716","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M et al (2023) Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology 240:109716. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109716","journal-title":"Neuropharmacology"},{"issue":"3","key":"5037_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrd3366","volume":"10","author":"AH Nagahara","year":"2011","unstructured":"Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10(3):209\u2013219. https:\/\/doi.org\/10.1038\/nrd3366","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5037_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138(2):155\u2013175. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.01.004","journal-title":"Pharmacol Ther"},{"issue":"2","key":"5037_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BST20140016","volume":"42","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher C (2014) Insulin, incretins and other growth factors as potential novel treatments for Alzheimer\u2019s and Parkinson\u2019s diseases. Biochem Soc Trans 42(2):593\u2013599. https:\/\/doi.org\/10.1042\/BST20140016","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"5037_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.14283\/jpad.2024.6","volume":"11","author":"L Hao","year":"2024","unstructured":"Hao L, Shi M, Ma J, Shao S, Yuan Y, Liu J (2024) A cholecystokinin analogue ameliorates cognitive deficits and regulates mitochondrial dynamics via the AMPK\/Drp1 pathway in APP\/PS1 mice. J Prev Alzheimers Dis 11(2):382\u2013401. https:\/\/doi.org\/10.14283\/jpad.2024.6","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"5037_CR45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3233\/jad-2002-4605","volume":"4","author":"T Perry","year":"2002","unstructured":"Perry T, Greig NH (2002) The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer\u2019s disease. J Alzheimers Dis 4(6):487\u2013496. https:\/\/doi.org\/10.3233\/jad-2002-4605","journal-title":"J Alzheimers Dis"},{"key":"5037_CR46","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review. Front Neurosci 16:970925. https:\/\/doi.org\/10.3389\/fnins.2022.970925","journal-title":"Front Neurosci"},{"issue":"1\u20133","key":"5037_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejphar.2008.03.025","volume":"587","author":"VA Gault","year":"2008","unstructured":"Gault VA, H\u00f6lscher C (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 587(1\u20133):112\u2013117. https:\/\/doi.org\/10.1016\/j.ejphar.2008.03.025","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"5037_CR48","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI57256","volume":"122","author":"TR Bomfim","year":"2012","unstructured":"Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease- associated A\u03b2 oligomers. J Clin Invest 122(4):1339\u20131353. https:\/\/doi.org\/10.1172\/JCI57256","journal-title":"J Clin Invest"},{"key":"5037_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","volume":"277","author":"HY Cai","year":"2014","unstructured":"Cai HY, H\u00f6lscher C, Yue XH, Zhang SX, Wang XH, Qiao F (2014) Lixisenatide rescues spatial memory and synaptic plasticity from amyloid \u03b2 protein-induced impairments in rats. Neuroscience 277:6\u201313. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.02.022","journal-title":"Neuroscience"},{"key":"5037_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"86","author":"PL McClean","year":"2014","unstructured":"McClean PL, H\u00f6lscher C (2014) Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology 86:241\u2013258. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.07.015","journal-title":"Neuropharmacology"},{"issue":"1","key":"5037_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jnc.13736","volume":"139","author":"J Jalewa","year":"2016","unstructured":"Jalewa J, Sharma MK, H\u00f6lscher C (2016) Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J Neurochem 139(1):55\u201367. https:\/\/doi.org\/10.1111\/jnc.13736","journal-title":"J Neurochem"},{"issue":"10103","key":"5037_CR52","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"issue":"13","key":"5037_CR53","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to JL (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"key":"5037_CR54","doi-asserted-by":"publisher","first-page":"153331752095304","DOI":"10.1177\/1533317520953041","volume":"35","author":"M Maskery","year":"2020","unstructured":"Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, H\u00f6lscher C (2020) The Dual GLP-1\/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP\/PS1 Mouse Model of Alzheimer\u2019s Disease. Am J Alzheimers Dis Other Demen 35:1533317520953041. https:\/\/doi.org\/10.1177\/1533317520953041","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"4","key":"5037_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bph.15508","volume":"179","author":"C H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher C (2022) Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol 179(4):695\u2013714. https:\/\/doi.org\/10.1111\/bph.15508","journal-title":"Br J Pharmacol"},{"key":"5037_CR56","doi-asserted-by":"publisher","first-page":"7427136","DOI":"10.1155\/2023\/7427136","volume":"2023","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Shi M, Li Z, Ling Y, Zhai L, Yuan Y et al (2023) A Dual GLP-1\/GIP receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson\u2019s disease. Parkinsons Dis 2023:7427136. https:\/\/doi.org\/10.1155\/2023\/7427136","journal-title":"Parkinsons Dis"},{"issue":"3","key":"5037_CR57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1124\/mol.111.074757","volume":"81","author":"D Schelshorn","year":"2012","unstructured":"Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, Mutel V et al (2012) Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol Pharmacol 81(3):309\u2013318. https:\/\/doi.org\/10.1124\/mol.111.074757","journal-title":"Mol Pharmacol"},{"key":"5037_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.npep.2015.09.010","volume":"55","author":"CR G\u00f8tzsche","year":"2016","unstructured":"G\u00f8tzsche CR, Woldbye DP (2016) The role of NPY in learning and memory. Neuropeptides 55:79\u201389. https:\/\/doi.org\/10.1016\/j.npep.2015.09.010","journal-title":"Neuropeptides"},{"issue":"1633","key":"5037_CR59","doi-asserted-by":"publisher","first-page":"20130155","DOI":"10.3389\/fnsyn.2013.00003","volume":"369","author":"AJ Irving","year":"2013","unstructured":"Irving AJ, Harvey J (2013) Leptin regulation of hippocampal synaptic function in health and disease. Philos Trans R Soc Lond B Biol Sci 369(1633):20130155. https:\/\/doi.org\/10.3389\/fnsyn.2013.00003","journal-title":"Philos Trans R Soc Lond B Biol Sci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05037-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T04:06:59Z","timestamp":1755662819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05037-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5037"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05037-7","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animals were treated according to the guidelines for the Care and Use of Laboratory Animals and the experimental procedures were approved by the Animal Care and Use Committee of Henan University of Chinese Medicine (approval no. IACUC-202304018).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}